BNTX:NASDAQ
BioNTech SE - ADR
US$ ९५.२५
arrow_downward
-०.५०%(-०.४८) 1D
US$ ९६.००
arrow_upward
+०.७९% (+०.७५)bedtimeAfter hours
Closed: अक्टोबर ७, १६:००:०१ GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
US$ ९५.१७
High
US$ ९७.४६
Low
US$ ९३.९२
Mkt. cap
२३.९३ अरब
Avg. vol.
१०.१३ लाख
Volume
८.२८ लाख
52-wk high
US$ १२३.९८
52-wk low
US$ ७९.५२
EPS
-US$ ७.५५
Beta
१.२२
Shares outstanding
२५.१२ करोड
No. of employees
८ हजार
Open
US$ ९५.१७
High
US$ ९७.४६
Low
US$ ९३.९२
Mkt. cap
२३.९३ अरब
Avg. vol.
१०.१३ लाख
Volume
८.२८ लाख
52-wk high
US$ १२३.९८
52-wk low
US$ ७९.५२
EPS
-US$ ७.५५
Beta
१.२२
Shares outstanding
२५.१२ करोड
No. of employees
८ हजार
News stories
From web sources and news partners
GuruFocus
·
५ घण्टा पहिले
BNTX Maintained by Morgan Stanley -- Price Target Lowered to $11
Investing.com Nigeria
·
१७ घण्टा पहिले
Form 4 BioNTech SE For: 7 October By Investing.com
AD HOC NEWS
·
२३ घण्टा पहिले
BioNTech stock fell 1.96 percent despite a Buy consensus
Yahoo Finance
·
२ दिन पहिले
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR